nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.02.2005 | Review

Immunoprevention and immunotherapy of cancer in ageing

verfasst von: Mauro Provinciali, Arianna Smorlesi

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Over the last few years there has been a growing interest in geriatric oncology, mainly because of the evidence that advanced age is the greatest risk factor for the development of cancer and that, since the elderly population is rapidly expanding, so too will the number of cancer patients. This forecast necessitates the development of new and more specific strategies for the prevention and cure of cancer in the elderly and as a result an ever-increasing need for oncologists, geriatricians and researchers to work closely together. The increased incidence of cancer in elderly people has been related to the age-associated changes occurring in the immune system, the so-called immunosenescence. This phenomenon is best characterised by a remodelling of the immune system, which appears early on and progresses throughout a person’s life and mainly involves a decrease in cellular functions. This review aims to provide a rationale for the development of specific immunotherapeutic and immunopreventive regimens for the elderly. We also include a discussion on the influence that immunosenescence has on the growth of tumours and the effectiveness of immunogene therapy and cancer vaccination following a brief analysis of the age-related alterations of the cell populations involved in antitumour immunity.

Thoman ML, Weigle WO (1989) The cellular and subcellular bases of immunosenescence. In: Dixon FJ (ed) Advances in immunology, vol 46. Academic, San Diego, p 221

Miller RA (1996) The ageing immune system: primer and prospectus. Science 273:70PubMed

Pawelec G, Solana R (1997) Immunosenescence. Trend Immunol 11:514

Burns EA, Goodwin JS (1998) Immunological changes of aging. In: Balducci L, Lyman GH, Ershler WB (eds) Comprehensive geriatric oncology. Harwood Academic Publishers, The Netherlands, p 213

Hoffmann JA, Kafatos FC, Janeway CA Jr, Ezekowitz RAB (1999) Phylogenetic perspectives in innate immunity. Science 284:1313CrossRefPubMed

Fabris E, Mocchegiani, Provinciali M (1994) Plasticity of neuroendocrine-immune interactions during aging. In: Berczi I, Szèlenyi J (eds) Advances in psychoneuroimmunology. Plenum, New York, p 331

George AJ, Ritter MA (1996) Thymic involution with ageing: obsolescence or good housekeeping? Immunol Today 17:267CrossRefPubMed

Solana R, Pawelec G (1998) Molecular and cellular basis of immunosenescence. Mech Ageing Dev 102:115CrossRefPubMed

Shearer GM (1997) Th1/Th2 changes in aging. Mech Ageing Dev 94:1CrossRef

10.

Rink L, Cakman I, Kirchner H (1998) Altered cytokine production in the elderly. Mech Ageing Dev 102:199CrossRefPubMed

11.

Miller JP, Allman D (2003) The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol 171:2326PubMed

12.

Sailey RW, Eun SY, Russell CE, Vogel LA (2001) B cells of aged mice show decreased expansion in response to antigen, but are normal in effector function. Cell Immunol 214:99CrossRefPubMed

13.

Ershler WB, Moore AL, Socinski MA (1984) Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol 4:445PubMed

14.

Kishimoto S, Tomino S, Mitsuya H, Nishimura H (1982) Age-related decrease in frequencies of B-cell precursors and specific helper T cells involved in the IgG anti-tetanus toxoid antibody production in humans. Clin Immunol Immunopathol 25:1CrossRefPubMed

15.

Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23(9):445CrossRefPubMed

16.

Effros RB, Walford RL (1984) The effect of age on the antigen-presenting mechanism in limiting diluition precursor cell frequency analysis. Cell Immunol 88:531PubMed

17.

Miller C, Kelsoe G, Han S (1994) Lack of B7-2 expression in the germinal centers of aged mice. Ageing Immunol Infect Dis 5:249

18.

Donnini A, Argentati K, Mancini R, Smorlesi A, Bartozzi B, Bernardini G, Provinciali M (2002) Phenotype antigen-presenting capacity, and migration of antigen-presenting cells in young and old age. Exp Gerontol 37:1097CrossRefPubMed

19.

Provinciali M, Donnini A, Re F (2004) MHC-unrestricted cytotoxicity in ageing. In: Straub RH, Mocchegiani E (eds) The neuroendocrine immune network in ageing. Neuroimmune biology, vol 4. Elsevier, Amsterdam

20.

Carrard G, Bulteau AL, Petropoulos I, Friguet B (2002) Impairment of proteasome structure and function in aging Int J Biochem Clee Biol 34:1461CrossRef

21.

Mishto M, Santoro A, Bellavista E, Bonafe M, Monti D, Franceschi C (2003) Immunoproteasomes and immunosenescence. Ageing Res Rev 2:419CrossRefPubMed

22.

Lung TL, Saurwein-Teissl M, Parson W, Schonitzer D, Grubeck-Loebenstein B (2000) Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine 18:1606CrossRefPubMed

23.

Steger MM, Maczek C, Grubeck-Loebenstein B (1996a) Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Clin Exp Immunol 105:544CrossRefPubMed

24.

Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675CrossRefPubMed

25.

Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S (2002) Cutting edge: impaired Toll-like receptor expression and function in ageing. J Immunol 169:4697PubMed

26.

Franc NC, White K, Ezekowitz RA (1999) Phagocytosis and development: back to the future. Curr Opin Immunol 11:47CrossRefPubMed

27.

Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164:558PubMed

28.

Castle S, Uyemura K, Wong W, Modlin RL, Effros R (1997) Evidence of enhanced type 2 immune response and impaired up-regulation of a type 1 response in frail elderly nursing home residents. Mech Ageing Dev 94:7CrossRefPubMed

29.

Frasca D, Pucci S, Goso C, Barattini P, Barile S, Pioli C, Doria G (1997) Regulation of cytokine production in aging: use of recombinant cytokines to upregulate mitogen-stimulated spleen cells. Mech Ageing Dev 93:157CrossRefPubMed

30.

Lio D, D’Anna C, Gervasi F, Scola L, Potestio M, Di Lorenzo G, Listi F, Colombo A, Candore G, Caruso C (1998) Interleukin-12 release by mitogen-stimulated mononuclear cells in the elderly. Mech Ageing Dev 102:211CrossRefPubMed

31.

Ershler W, Longo DL (1997) Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 8:1489CrossRef

32.

Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624CrossRefPubMed

33.

Bar-Eli M, Gallily R (1979) Age-dependent macrophage functions in New Zealand black mice. Cell Immunol 45:309PubMed

34.

Jaroslow BN, Larrick JW (1973) Clearance of foreign red cells from the blood of ageing mice. Mech Ageing Dev 2:23CrossRefPubMed

35.

Sadeghi HM, Schnelle JF, Thoma JK, Nishanian P, Fahey JL (1999) Phenotypic and functional characteristics of circulating monocytes of elderly persons. Exp Gerontol 34:959CrossRefPubMed

36.

O’Mahony L, Holland J, Jackson J, Feighery C, Hennessy TP, Mealy K (1998) Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production. Clin Exp Immunol 113:213CrossRefPubMed

37.

Ahluwalia N, Mastro AM, Ball R, Miles MP, Rajendra R, Handte G (2001) Cytokine production by stimulated mononuclear cells did not change with ageing in apparently healthy, well-nourished women. Mech Ageing Dev 122:1269CrossRefPubMed

38.

McLachlan JA, Serkin CD, Morrey KM, Bakouche O (1995) Antitumoral properties of aged human monocytes. J Immunol 154:832PubMed

39.

Corsini E, Battaini F, Lucchi L, Marinovich M, Racchi M, Govoni S, Galli CL (1999) Reduction of transendothelial migration of mononuclear cells in interferon-beta1b-treated multiple sclerosis patients. Ann Neurol 46:435CrossRefPubMed

40.

Khare V, Sodhi A, Singh SM (1996) Effect of ageing on the tumoricidal functions of murine peritoneal macrophages. Nat Immun 15:285PubMed

41.

Wallace PK, Eisenstein TK, Meissler JJ Jr, Morahan PS (1995) Decreases in macrophage mediated antitumor activity with aging. Mech Ageing Dev 77:169CrossRefPubMed

42.

Herrero C, Marques L, Lloberas J, Celada A (2001) IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice. J Clin Invest 107:485PubMed

43.

Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G (1992) Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149:3627PubMed

44.

Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G (1997) Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89(14):1049CrossRefPubMed

45.

Angelis P, Scharf S, Christophidis N (1997) Effects of age on neutrophil function and its relevance to bacterial infections in the elderly. J Clin Lab Immunol 49:33PubMed

46.

Born J, Uthgenannt D, Dodt C, Nunninghoff D, Ringvolt E, Wagner T, Fehm HL (1995) Cytokine production and lymphocyte subpopulations in aged humans: an assessment during nocturnal sleep. Mech Ageing Dev 84:113CrossRefPubMed

47.

Chatta GS, Andrews RG, Rodger E, Schrag M, Hammond WP, Dale DC (1993) Hematopoietic progenitors and ageing: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. J Gerontol 48:M207PubMed

48.

MacGregor RR, Shalit M (1990) Neutrophil function in healthy elderly subjects. J Gerontol 45:M55–60PubMed

49.

Phair JP, Kauffman CA, Bjornson A, Gallagher J, Adams L, Hess EV (1978) Host defenses in the aged: evaluation of components of the inflammatory and immune responses. J Infect Dis 138:67PubMed

50.

Corberand J, Ngyen F, Laharrague P, Fontanilles AM, Gleyzes B, Gyrard E, Senegas C (1981) Polymorphonuclear functions and ageing in humans. J Am Geriatr Soc 29:391PubMed

51.

McLaughlin B, O’Malley K, Cotter TG (1986) Age-related differences in granulocyte chemotaxis and degranulation. Clin Sci (Lond) 70:59

52.

Antonaci S, Jirillo E, Ventura MT, Garofalo AR, Bonomo L (1984) Non-specific immunity in ageing: deficiency of monocyte and polymorphonuclear cell-mediated functions. Mech Ageing Dev 24:367CrossRefPubMed

53.

Charpentier B, Fournier C, Fries D, Mathieu D, Noury J, Bach JF (1981) Immunological studies in human ageing. I. In vitro functions of T cells and polymorphs. J Clin Lab Immunol 5:87PubMed

54.

Corberand JX, Laharrague PF, Fillola G (1986) Neutrophils are normal in normal aged humans. J Leukoc Biol 40:333PubMed

55.

Lipschitz DA, Udupa KB, Boxer LA (1988) The role of calcium in the age-related decline of neutrophil function. Blood 71:659PubMed

56.

Fulop T Jr, Foris G, Worum I, Leovey A (1985) Age-dependent alterations of Fc gamma receptor-mediated effector functions of human polymorphonuclear leucocytes. Clin Exp Immunol 61:425PubMed

57.

Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Pena J, Solana R (1999) NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 34:253CrossRefPubMed

58.

Kutza J, Murasko DM (1996) Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Mech Ageing Dev 90:209CrossRefPubMed

59.

Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, Marcato A, Passeri G, Ortolani C, Forti E (1993) Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82:2767PubMed

60.

Rabinowich H, Goses Y, Reshef T, Klajman A (1985) Interleukin-2 production and activity in aged humans. Mech Ageing Dev 32:213CrossRefPubMed

61.

Bender BS, Chrest FJ, Adler WH (1986) Phenotypic expression of natural killer cell associated membrane antigens and cytolytic function of peripheral blood cells from different aged humans. J Clin Lab Immunol 21:31PubMed

62.

Sato T, Fuse A, Kuwata T (1979) Enhancement by IFN of natural cytotoxic ativity of lymphocytes from human cord blood and peripheral blood of aged persons. Cell Immunol 45:458PubMed

63.

Bruunsgaard H, Pedersen AN, Schroll M, Skinhoj P, Pedersen BK (2001) Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol 37:127CrossRefPubMed

64.

Provinciali M, Di Stefano G, Stronati S, Fabris N (1998) Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients. Cytokine 10(2):132CrossRefPubMed

65.

Solana R, Alonso MC, Pena J (1999) Natural killer cells in healthy ageing. Exp Gerontol 34:435CrossRefPubMed

66.

Bubenik J, Cinader B, Indrova M, Koh SW, Chou CT (1987) Lymphokine-activated killer (LAK) cells, I: age-dependent decline of LAK cell-mediated cytotoxicity. Immunol Lett 16:113CrossRefPubMed

67.

Bykovskaya SN, Abronina IF, Kupriyanova TA, Bubenik J (1990) Down-regulation of LAK cell-mediated cytotoxicity: cancer and ageing. Biomed Pharmacother 44:333CrossRefPubMed

68.

Lipschitz DA, Udupa KB, Milton KY, Thompson CO (1984) Effect of age on hematopoiesis in man. Blood 63:502PubMed

69.

Provinciali M, Di Stefano G, Fabris N (1995) Evaluation of LAK cell development in young and old healthy humans. Nat Immun 14:134PubMed

70.

Krishnaraj R (1997) Senescence and cytokines modulate the NK cell expression. Mech Ageing Dev 96:89CrossRefPubMed

71.

Mariani E, Pulsatelli L, Meneghetti A, Dolzani P, Mazzetti I, Neri S, Ravaglia G, Forti P, Facchini A (2001) Different IL-8 production by T and NK lymphocytes in elderly subjects. Mech Ageing Dev 122:1383CrossRefPubMed

72.

Fabris N, Provinciali M (1989) Hormones. In: Nelson D (ed) Natural immunity. Academic, New York, p 306

73.

Fabris N, Mocchegiani E, Provinciali M (1997) Plasticity of neuroendocrine-thymus interactions during aging. Exp Gerontol 32:415CrossRefPubMed

74.

Provinciali M, Muzzioli M, Di Stefano G, Fabris N (1991) Recovery of spleen cell natural killer activity by thyroid hormone treatment in old mice. Nat Immun Cell Growth Regul 10:22

75.

Provinciali M, Di Stefano G, Bulian D, Stronati S, Fabris N (1997) Long-term melatonin supplementation does not recover the impairment of natural killer cell activity and lymphocyte proliferation in aging mice. Life Sci 67:857CrossRef

76.

Provinciali M, Fabris, Pieri C (1990) Improvement of natural killer cell activity by in vitro active lipids (AL 721) administration in old mice. Mech Ageing Dev 52:245CrossRefPubMed

77.

Provinciali M, Pieri C, Fabris N (1991) Reversibility of age associated NK defect by endocrinological and/or nutritional intervention. Ann Ist Super Sanità 27:61

78.

Provinciali M, Di Stefano G, Bernardi A, Fabris N (1990) Role of pituitary-thyroid axis on basal and lymphokine-induced NK cell activity in ageing. Int J Neurosci 51:273PubMed

79.

Argentati K, Bartozzi B, Bernardini G, Di Stasio G, Provinciali M (2000) Induction of NK cell activity and perforin and Granzyme B expression following continuous culture or short pulse with IL-12 in young and old mice. Eur Cytokine Netw 11:59–65PubMed

80.

Bloom ET, Kubota LF (1989) Effect of IL-2 in vitro on CTL generation in spleen cells of young and old mice: asialo GM1+ cells are required for the apparent restoration of the CTL response. Cell Immunol 119:73PubMed

81.

Kawakami K, Bloom ET (1987) Lymphokine-activated killer cells and ageing in mice: significance for defining the precursor cell. Mech Ageing Dev 41:229CrossRefPubMed

82.

Kawakami K, Bloom ET (1988) Lymphokine-activated killer cells derived from murine bone marrow: age-associated difference in precursor cell populations demonstrated by response to interferon. Cell Immunol 116:163PubMed

83.

Saxena RK, Saxena QB, Adler W (1984) WH Interleukin-2-induced activation of natural killer activity in spleen cells from old and young mice. Immunology 51:719PubMed

84.

Poccia F, Gougeon ML, Bonneville M, Lopez-Botet M, Moretta A, Battistini L, Wallace M, Colizzi V, Malkovsky M (1998) Innate T-cell immunity to nonpeptidic antigens. Immunol Today 19:253CrossRefPubMed

85.

Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, Fournie JJ (1994) Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264:267PubMed

86.

Cipriani B, Borsellino G, Poccia F, Placido R, Tramonti D, Bach S, Battistini L, Brosnan CF (2000) Activation of C-C beta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 95:39PubMed

87.

Giachino C, Granziero L, Modena V, Maiocco V, Lomater C, Fantini F, Lanzavecchia A, Migone N (1994) Clonal expansions of V delta 1+ and V delta 2+ cells increase with age and limit the repertoire of human gamma delta T cells. Eur J Immunol 24:1914PubMed

88.

Argentati K, Re F, Donnini A, Tucci MG, Franceschi C, Bartozzi B, Bernardini G, Provinciali M (2002) Numerical and functional alterations of circulating γδT lymphocytes in aged people and centenarians. J Leukoc Biol 72:65PubMed

89.

Colonna-Romano G, Potestio M, Aquino A, Candore G, Lio D, Caruso C (2002) Gamma/delta T lymphocytes are affected in the elderly. Exp Gerontol 37:205CrossRefPubMed

90.

Walker PR, Saas P, Dietrich P-Y (1997) Role of Fas Ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158:4521PubMed

91.

Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lavagetto G, Casti A, Franceschi C, Passeri M, Sansoni P (2000) Shortage of circulating naive CD8⁺ T cells provides new insights on immunodeficiency in aging. Blood 95:2860PubMed

92.

Zhou D, Chrest FJ, Adler W, Munster A, Winchurch RA (1993) Increased production of TGF-beta and IL-6 by aged spleen cells. Immunol Lett 36:7CrossRefPubMed

93.

Goodwin JS, Messner RP (1979) Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70. J Clin Invest 64:434PubMed

94.

Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS (1999) Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-il18, and IL-1 beta converting enxyme cDNA. Proc Natl Acad Sci U S A 96:13351CrossRefPubMed

95.

Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison CL, Moen RC, Gauldie J, Graham FL (1999) Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 6:350CrossRefPubMed

96.

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707PubMed

97.

Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50(13):4087PubMed

98.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54(1):16PubMed

99.

Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15(11):3363PubMed

100.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181(6):2109CrossRefPubMed

101.

Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 92(2):432PubMed

102.

Cahill DP, Kinzler KW, Vogelstein B, Lengaver C (1999) Genetic instability and Darwinian selection in tumours. Trends Cell Biol 9:M57CrossRefPubMed

103.

Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15(2):48CrossRefPubMed

104.

Amici A, Smorlesi A, Noce G, Santoni G, Cappelletti P, Capparuccia L, Coppari R, Lucciarini R, Petrelli F, Provinciali M (2000) DNA vaccination with full-length or truncated Neu induced protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 7:703CrossRefPubMed

105.

Pawelec G, Hirokawa K, Fulop T (2001) Altered T cell signalling in ageing. Mech Ageing Dev 122:1613CrossRefPubMed

106.

Kapasi ZF, Murali-Krishna K, McRae ML, Ahmed R (2002) Defective generation but normal maintenance of memory T cells in old mice. Eur J Immunol 32:1567CrossRefPubMed

107.

Pawelec G, Solana R, Remarque ED, Mariani E (1998) Impact of aging on innate immunity. J Leukoc Biol 64:703PubMed

108.

Provinciali M, Di Stefano G, Colombo M, Della Croce F, Gandolfi MC, Daghetta L, Anichini M, Della Bitta R, Fabris N (1994) Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech Ageing Dev 77:75CrossRef

109.

Provinciali M, Montenovo A, Di Stefano G, Colombo M, Daghetta L, Cairati M, Veroni C, Cassino R, Della Torre F, Fabris N (1998) Effect of zinc or zinc plus arginine supplementation on antibody titer and lymphocyte subsets after influenza virus vaccination in elderly subjects. Age Ageing 27:715PubMed

110.

Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW (2003) Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348:1747CrossRefPubMed

111.

Steger MM, Maczek C, Berger P, Grubeck-Loebenstein B (1996b) Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection? Lancet 348:762

112.

Wolters B, Junge U, Dziuba S, Roggendorf M (2003). Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21:3623CrossRefPubMed

113.

Miller RA, Chrisp C (2002) T cell subset patterns that predicts resistance to spontaneous lymphoma, mammary adenocarcinoma, and fibrosarcoma in mice. J Immunol 169:1619PubMed

114.

Argentati K, Re F, Serresi S, Tucci MG, Bartozzi B, Bernardini G, Provinciali M (2003) Reduced number and impaired function of circulating gammadelta T cells in patients with cutaneous primary melanoma. J Invest Dermatol 120(5):829PubMed

115.

Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A (2003) Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21(9–10):843

116.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettighausen JE, Matori YL, Skibberg JM, Shiloni E, Vetto JV, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant IL-2 to patients with metastatic cancer. N Engl J Med 313:1485PubMed

117.

Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622CrossRefPubMed

118.

Dussault I, Miller SC (1994). Decline in natural killer cell-mediated immunosurveillance in aging mice: a consequence of reduced cell production and tumor binding capacity. Mech Ageing Dev 75:115CrossRefPubMed

119.

Negrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, Merrouche Y, Oskam R, Franks CR, Clavel Mmoskovtchenko JF, Philip T (1992) Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br J Cancer 65:723PubMed

120.

Dussault I, Miller SC (1995) Effectiveness of immunotherapy in aged leukemic mice. Gerontology 41:204

121.

Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Immunol 3:630CrossRef

122.

Ko BK, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG (2003) Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9:3222PubMed

123.

Lollini P-L, Forni G (2003) Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 24:62CrossRefPubMed

124.

Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaio M, Colombo MP, Amici A, Lollini PL, Musini P, Forni G (2003) Nonredundant roles of antibody, cytokines and perforin for the immune eradication of established HER-2/neu carcinomas. J Clin Invest 111:1161CrossRefPubMed

125.

Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML (2002) Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 9:33PubMed

126.

Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J (2001) Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101:192CrossRefPubMed

127.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624CrossRefPubMed

128.

Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ (2003) Mucin-1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26:47CrossRefPubMed

129.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850CrossRefPubMed

130.

Kaesberg PR, Ershler WB (1989) The importance of immunosenescence in the incidence and malignant properties of cancer in hosts of advancer age. J Gerontol 44:63PubMed

131.

Seymour K, Pettit S, O’Flaherty E, Charnley RM, Kirby JA (1999) Selection of metastatic tumor phenotypes by host immune systems. Lancet 354:1989CrossRefPubMed

132.

Kreisle RA, Stebler BA, Ershler WB (1990) Effect of host age on tumor-associated angiogenesis in mice. J Natl Cancer Inst 82:44PubMed

133.

Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A (1994) Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst 86:1303PubMed

134.

Onozuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 monoclonal antibody. Cancer Res 59:3128PubMed

135.

Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity 2:1PubMed

136.

Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P (2002) CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A 99:8832CrossRefPubMed

Titel: Immunoprevention and immunotherapy of cancer in ageing
verfasst von: Mauro Provinciali
Arianna Smorlesi
Publikationsdatum: 01.02.2005
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2005
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0539-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Immunoprevention and immunotherapy of cancer in ageing

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2005

Cachexia induced by Walker 256 tumor growth causes rat lymphocyte death

Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo

High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity

A CD80-transfected human breast cancer cell variant induces HER-2/neu–specific T cells in HLA-A*02–matched situations in vitro as well as in vivo

A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour

Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie